Trendlines Group

What Trendlines Group does

Trendlines Group is a publicly listed (SGX: 42T; OTCQX: TRNLY) startup incubator and venture capital firm headquartered in Misgav, Israel with a regional office in Singapore. The company invests in seed and early-stage companies developing proprietary technologies in two verticals: agrifood (e.g., Phytolon's fermentation-based natural food colors, AgroScout's AI crop monitoring, Celleste Bio's cell-cultured cocoa, IBI Ag's bioinsecticides) and medtech (e.g., Escala Medical's incision-free POP repair, Vensica's needle-free ultrasound drug delivery, Limaca's Precision-GI biopsy device, ElastiMed's electroactive polymer wearables, ZygoFix's lumbar facet fixation, Ceretrieve's stroke aspiration catheter).

The business model combines fund management (Trendlines Agrifood Fund, formerly with Temasek and Librae Holdings as $22M anchor LPs; Bayer Trendlines Ag Innovation Fund until its December 2024 dissolution; the newly partnered Proterra Trendlines Fund) with hands-on equity investing across the portfolio lifecycle. Trendlines takes an operating role in technology development, regulatory navigation, business building and commercialization, and monetizes through management fees, carried interest (60% retained in the Proterra vehicle) and equity returns at exit, illustrated by the ApiFix sale to OrthoPediatrics (2020) and OrthoSpin sale to Johnson & Johnson (2021).

Following a strategic pivot in 2024–2025 that included leadership changes, the dissolution of the Bayer vehicle, disposal of business units, technical merger of a subsidiary, and a ~60% reduction in operating costs, Trendlines returned to profitability in FY2025. The company continues to drive portfolio company momentum, with Phytolon securing FDA approval for Beetroot Red and a $23.6M Series B in 2026, Vensica receiving FDA IND clearance for a Phase 2 trial, and ElastiMed entering the US market via a distribution partnership.

Name

Trendlines Group

Legal name

The Trendlines Group Ltd.

Website

https://trendlines.com

Company type

Public

Founded year

2007

Operating status

Operating

Headcount range

11–50 employees

Short description

Trendlines Group is a publicly listed Israel- and Singapore-based incubator that invests in and supports early-stage agrifood and medtech startups, generating returns through fund management fees, carried interest, and equity exits from its hands-on portfolio.

Ownership category

akta.pro rank

Product category

Venture Capital Incubation

NAICS

Portfolio Management and Investment Advice (523940)

SIC

Investment Advice (6282)

akta.pro primary industry

Transition / Engagement & Stewardship Funds (FSANAJAO)

akta.pro secondary industry

Sustainability & ESG Consulting (BPAHACAK)

Keywords

• Venture capital incubation
• Medtech investment
• Agrifood innovation
• Seed-stage funding
• Startup incubation

Headquarters

HQ city

Misgav

HQ country

Israel

HQ region

Middle East

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D

Revenue model

1. Portfolio Investment Returns: Trendlines generates returns through equity investments in portfolio companies. The company returns to profitability in FY2025 after strategic pivot, supported by gains from portfolio companies and strategic exits.
2. Fund Management Fees: The company manages venture funds including the Trendlines Agrifood Fund, receiving management fees and carried interest (Proterra receives 40% of carried interests while Trendlines retains 60%).

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Core offering

Trendlines Group is a publicly listed (SGX: 42T; OTCQX: TRNLY) startup incubator and venture capital investor focused on innovation-based medical and agrifood technologies. The company takes a hands-on approach, investing in seed-stage companies and providing operational support from technology development through business building. It manages specialized funds including the Trendlines Agrifood Fund (now Proterra Trendlines Fund) and previously the Bayer Trendlines Ag Innovation Fund.

Product overview

Trendlines Group is a Singapore-listed startup incubator and investor focused on agrifood and medtech innovations. The company does not offer a single unified product but rather invests in and supports portfolio companies developing distinct technologies. In agrifood, key portfolio companies include Phytolon (natural food colors via fermentation), AgroScout (AI crop monitoring), Celleste Bio (cell-cultured cocoa), IBI Ag (bioinsecticides), and others. In medtech, portfolio includes Escala Medical (pelvic organ prolapse repair device), ElastiMed (wearable compression devices), Vensica Medical (needle-free drug delivery), Limaca Medical (endoscopic biopsy devices), and others spanning urology, orthopedics, aesthetics, and surgical applications.

Differentiator

Problem solved

Functional benefit

Brands

• Trendlines Agrifood Fund: Agrifood-focused investment fund originally launched in 2019 with anchor commitments from Temasek and Librae Holdings, renamed Proterra Trendlines Fund under new management by Proterra Investment Advisors.
• Bayer Trendlines Ag Innovation Fund
• Trendlines Innovation Labs

Products and services

• Trendlines Agrifood Fund (Proterra Trendlines Fund)

Quantifiable outcome

• Returned to profitability in FY2025 after 60% operating cost reduction
• +2 more outcomes

Named customers6 records

Segments4 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Six partnerships are on record, tiered core and flagship.

• LaboriecoreStrategic or Co-development Partner · 1 January 2023Laborie, a prominent urology medical device company, is a strategic partner and investor in Vensica Medical supporting Phase 2 trials.
• HekaBiocoreChannel Partner/ Reseller/ Distributor · 1 May 2022HekaBio K.K. is the distribution partner for Limaca Medical's Precision-GI Endoscopic Biopsy Device in Japan, providing full operational capability and ensuring PMDA regulatory compliance.
• Merz TherapeuticsflagshipStrategic or Co-development Partner · 1 August 2021Vensica Medical (Trendlines portfolio company) has a strategic partnership with Merz Therapeutics, licensing Xeomin for needle-free urological applications with exclusive rights in several indications.
• DSM-FirmenichflagshipChannel Partner/ Reseller/ Distributor · 1 January 2021Phytolon (Trendlines portfolio company) entered a commercial agreement with DSM for distribution of its natural food colors produced through baker's yeast fermentation.
• Ginkgo BioworkscoreStrategic or Co-development Partner · 1 January 2021Phytolon has an R&D collaboration agreement with Ginkgo Bioworks for production of natural food colors. Ginkgo provides in-kind investment in the form of Foundry services.
• Genesis BiologicscoreChannel Partner/ Reseller/ Distributor · 1 May 2020Genesis Biologics has a partnership agreement with Arcuro Medical for sales, marketing, and distribution of the SuperBall Meniscus Repair System in the United States.

Scale indicators6 records

Recent moves9 records

Expansion highlights5 records

Direct peers

• OurCrowd: Israel-based venture investing platform deploying capital into early-stage startups across sectors including agrifood and medical technologies. Operates a comparable model of curating and supporting portfolio companies from seed through growth, often co-investing with strategic corporates.
• Pontifax: Israel-based life-sciences venture capital firm investing in early- and growth-stage medtech and biotech companies. Directly comparable in geography and the Israeli medtech incubation thesis that underpins Trendlines' portfolio.
• AgFunder: Venture capital firm and platform focused exclusively on agrifood technology investments. Directly comparable to Trendlines' Agrifood Fund thesis around sustainable food, agtech, and food-tech commercialization.
• Cultivian Sandbox Ventures: US venture fund focused on agrifood technology investments spanning crop production, animal health, and food innovation. Closely comparable to the Trendlines Agrifood Fund in sector mandate and stage focus.
• Rainbow Medical: Israel-based medical device incubator that seeds, develops and spins out innovative healthcare technologies. Directly comparable in the Israeli medtech incubation model and operational hands-on support.
• Integra Holdings: Israeli holding company investing in early-stage life sciences and medtech ventures, supporting them from inception through commercialization. Comparable to Trendlines' Israeli medtech incubation and value-building role.

Broad incumbents

• Flagship Pioneering: Larger US-based innovation platform that both creates and funds breakthrough science companies across healthcare, sustainability and agriculture. Comparable operating model (in-house origination plus investment) but at materially greater scale and a broader sector mandate.
• ARCH Venture Partners: Established US deep-tech and life-sciences venture firm investing from seed through later stages. Comparable in deploying early-stage capital into science-based medtech and agritech platforms, though at substantially larger fund sizes.

Others

• Temasek Holdings: Singapore-headquartered sovereign investor and anchor LP in the Trendlines Agrifood Fund. Comparable as a large-scale, sustainability-aware investor in agrifood and healthcare innovation, but as an LP rather than a peer manager.
• Bayer CropScience (Leaps by Bayer): Strategic corporate venture arm previously partnering with Trendlines via the Bayer Trendlines Ag Innovation Fund. Comparable as a large agritech investor and LP/corporate partner co-investing in early-stage agricultural technologies alongside funds like Trendlines'.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/TrendlinesGroup
• Facebookfacebook.com/TrendlinesGroup
• LinkedInlinkedin.com/company/trendlines

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds12 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments66 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Trendlines Group